Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast CancerThomas Hatschek, Jonas Bergh, Theodoros Foukakis et al.|JAMA Oncology|2021Cited by 58
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 TrialAlexios Matikas, Theodoros Foukakis, Hemming Johansson et al.|Clinical Cancer Research|2022Cited by 41
Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?Jonas Bergh, Thomas Hatschek, Erika Isaksson-Friman et al.|Journal of Clinical Oncology|2019Cited by 21
Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safeÅsa Wickberg, Kenneth Villman, Göran Liljegren et al.|European Journal of Surgical Oncology|2018Cited by 21
Can Axillary Dissection be Avoided by Improved Molecular Biological Diagnosis?Thomas Lindahl, Jonas Bergh, Georg Engel et al.|Acta Oncologica|2000Cited by 17